Asia Generic Pharmaceuticals Forecast Report; The

Summary

• Japan will be Asia's biggest branded generics market by the end of the decade, as the government continues to cut drug costs and make hospitals and consumers more price aware
• Australia will remain an attractive generics market, despite new access barriers created by the US free trade agreement and reform of the PBS
• China's generics market will continue to expand strongly, but success will depend on brand strength - as the population remains reliant on basic drugs
• India's patent law should clarify distinctions between so-called 'innovative' drugs and generics, with gradual insurance sector liberalisation driving demand
• Margins on generic drugs will look negative over the forecast period in Taiwan, as the public reimbursement system enters a period of crisis
• The strength of Korea's generic manufacturers will continue, but quality generics makers have little to fear from patent and pricing reform
• Exposure to international currency effects will increase import dependency for manufacturers in emerging Asian markets including Indonesia and the Philippines

Contents

Pricing Issues in Generic Drugs